Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 7/20 | 0.54 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | BMP1 | P13497 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509781 | 1.00 | AVPR1B (0.54) | AVPR1BAVPR1APLGITGB3ITGA2B | |
| SCHEMBL30007346 | 1.00 | AVPR1B (0.54) | AVPR1BAVPR1APLGITGB3ITGA2B | |
| SCHEMBL7898282 | 1.00 | AVPR1B (0.54) | AVPR1BAVPR1APLGITGB3ITGA2B | |
| SCHEMBL9329697 | 0.93 | AVPR1B (0.52) | AVPR1BAVPR1APLGBMP1F2 | |
| Phenylalanine SCHEMBL6286710 | 0.90 | AVPR1B (0.59) | AVPR1BAVPR1APLGBMP1F2 | |
| SCHEMBL2873083 | 0.88 | AVPR1B (0.48) | AVPR1BAVPR1APLGBMP1F2 | |
| SCHEMBL1738663 | 0.88 | AVPR1B (0.52) | AVPR1BAVPR1APLGBMP1 | |
| SCHEMBL29816989 | 0.88 | AVPR1B (0.48) | AVPR1BAVPR1APLGBMP1F2 | |
| SCHEMBL3501647 | 0.87 | AVPR1B (0.47) | AVPR1BAVPR1APLGBMP1F2 | |
| SCHEMBL7368157 | 0.87 | AVPR1B (0.47) | AVPR1BAVPR1APLGBMP1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897721-B2 | Cyclic peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7795378-B2 | Peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100121027-A1 | Cyclic Peptide Compositions for Treatment of Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| EP-1667700-A2 | CYCLIC PEPTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF SEXUAL DYSFUNCTION | Palatin Technologies, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050124553-A1 | Peptide compositions for treatment of sexual dysfunction | PALATINE TECHNOLOGIES, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2005014617-A2 | CYCLIC PEPTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF SEXUAL DYSFUNCTION | PALATIN TECHNOLOGIES, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20020168337-A1 | Sustained-release preparation | TAKADA CHEMICAL INDUSTRIES LTD. | 2002-11-14 | — | — | US | disclosed |
| EP-0822939-A1 | CYCLIC PENTAPEPTIDE LH-RH RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 1998-02-11 | — | — | EP | disclosed |
| EP-0815870-A2 | Composition for prohylaxis or treatment of cerebral infarction | Takeda Chemical Industries, Ltd. (JP) | 1998-01-07 | — | — | EP | disclosed |
| CN-1164192-A | Inhibitors of heterogeneously catalyzed proteases | CEPHALON INC (US) | 1997-11-05 | — | — | CN | disclosed |
| EP-0528312-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996034012-A1 | CYCLIC PENTAPEPTIDE LH-RH RECEPTOR ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-10-31 | — | — | WO | disclosed |
| EP-0714909-A1 | Composition for prophylaxis or treatment of pulmonary circulatory diseases | Takeda Chemical Industries, Ltd. (JP) | 1996-06-05 | — | — | EP | disclosed |
| EP-0647449-A1 | Sustained-release preparation of anti-endothelin substance | Takeda Chemical Industries, Ltd. (JP) | 1995-04-12 | — | — | EP | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| EP-0552417-A1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | disclosed |
| EP-0528312-A2 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020168337-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | AVPR1B 13/4885AVPR1A 15/4885PLG 230/4885 |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | AVPR1B 1003/4885AVPR1A 1073/4885PLG 2094/4885 |
| US-20050124553-A1 | Peptide compositions for treatment of sexual dysfunction | RXFP1, EDNRB, EDNRA | AVPR1B 31/4885AVPR1A 40/4885PLG 1543/4885 |
| US-20100121027-A1 | Cyclic Peptide Compositions for Treatment of Sexual Dysfunction | VIP, GNRHR, NPR1 | AVPR1B 12/4885AVPR1A 15/4885PLG 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.